JP2023538422A - 修飾ｉｌ－１８ポリペプチドおよびその使用 - Google Patents

修飾ｉｌ－１８ポリペプチドおよびその使用 Download PDF

Info

Publication number
JP2023538422A
JP2023538422A JP2023512669A JP2023512669A JP2023538422A JP 2023538422 A JP2023538422 A JP 2023538422A JP 2023512669 A JP2023512669 A JP 2023512669A JP 2023512669 A JP2023512669 A JP 2023512669A JP 2023538422 A JP2023538422 A JP 2023538422A
Authority
JP
Japan
Prior art keywords
polypeptide
modified
residue
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538422A5 (https=
Inventor
パタタビラマン，ウィジャヤ，ラーガヴァン
クレフト，ベルトルト
ベーリンガー，レジス
デロン，カミーユ
フェツ，クラウディア
フロール，アレクサンダー
ホルンスペルガー，ブノワ
キャラロット，ジャン－フィリップ
ボーデ，ジェフリー，ウィリアム
アレヴァロ－ルイス，マチルデ
ヴィードキア，アメリエ
ハイドン，アンナ
アイアコン，ロベルト
ワン，チョンチン
Original Assignee
ブライト ピーク セラピューティクス エージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブライト ピーク セラピューティクス エージー filed Critical ブライト ピーク セラピューティクス エージー
Publication of JP2023538422A publication Critical patent/JP2023538422A/ja
Publication of JP2023538422A5 publication Critical patent/JP2023538422A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023512669A 2020-08-19 2021-08-19 修飾ｉｌ－１８ポリペプチドおよびその使用 Pending JP2023538422A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067658P 2020-08-19 2020-08-19
US63/067,658 2020-08-19
PCT/IB2021/000574 WO2022038417A2 (en) 2020-08-19 2021-08-19 Modified il-18 polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2023538422A true JP2023538422A (ja) 2023-09-07
JP2023538422A5 JP2023538422A5 (https=) 2024-08-20

Family

ID=78032459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512669A Pending JP2023538422A (ja) 2020-08-19 2021-08-19 修飾ｉｌ－１８ポリペプチドおよびその使用

Country Status (9)

Country Link
US (1) US20220056091A1 (https=)
EP (1) EP4200323A2 (https=)
JP (1) JP2023538422A (https=)
KR (1) KR20230052956A (https=)
CN (1) CN116368148A (https=)
AU (1) AU2021327861A1 (https=)
CA (1) CA3189327A1 (https=)
IL (1) IL300638A (https=)
WO (1) WO2022038417A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
JP2023550545A (ja) * 2020-11-02 2023-12-01 シムハ・アイエル－１８・インコーポレイテッド インターロイキン－１８バリアントおよび使用の方法
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024102587A2 (en) * 2022-11-11 2024-05-16 Mural Oncology, Inc. Interleukin 18 variants
US20250186594A1 (en) * 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides modified with polymers
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004530432A (ja) * 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−１８変異体、その産生および使用
WO2019051015A1 (en) * 2017-09-06 2019-03-14 Yale University VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261244A3 (en) * 2003-04-15 2011-02-23 Glaxosmithkline LLC Human il-18 substitution mutants and their conjugates
US20160107999A1 (en) 2013-05-24 2016-04-21 Synaffix B.V. Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
US10266502B2 (en) 2014-01-24 2019-04-23 Synaffix B.V. Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
JP7128121B2 (ja) 2016-06-28 2022-08-30 ヴェンタナ メディカル システムズ， インク． Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004530432A (ja) * 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−１８変異体、その産生および使用
WO2019051015A1 (en) * 2017-09-06 2019-03-14 Yale University VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIRAKRIT SAETANG ET AL., PLOS ONE, vol. 11, no. 8, JPN6025034602, 2 August 2016 (2016-08-02), pages 0160321, ISSN: 0005798743 *
SOO-HYUN KIM ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 13, JPN7025003761, March 2002 (2002-03-01), pages 10998 - 11003, ISSN: 0005798742 *
YUTAKA YAMAMOTO ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 317, no. 1, JPN6025034603, April 2004 (2004-04-01), pages 181 - 186, ISSN: 0005798744 *

Also Published As

Publication number Publication date
WO2022038417A2 (en) 2022-02-24
KR20230052956A (ko) 2023-04-20
AU2021327861A1 (en) 2023-05-04
CN116368148A (zh) 2023-06-30
US20220056091A1 (en) 2022-02-24
EP4200323A2 (en) 2023-06-28
WO2022038417A3 (en) 2022-04-21
IL300638A (en) 2023-04-01
CA3189327A1 (en) 2022-02-24
AU2021327861A9 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
JP2023538422A (ja) 修飾ｉｌ－１８ポリペプチドおよびその使用
US12521441B2 (en) Modified IL-2 polypeptides and uses thereof
US8907053B2 (en) Immunosuppression modulating compounds
US20230357342A1 (en) Modified il-18 polypeptides
CN103450348B (zh) 一种促红细胞生成素模拟肽、其制备方法和用途
JP2016504335A (ja) Ａｐｊ受容体アゴニストおよびその使用
JP2019123719A (ja) インターロイキン−１０を疾病及び疾患の治療に用いる方法
US20040105840A1 (en) Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US20240116997A1 (en) Activatable il-18 polypeptides
US20230303649A1 (en) Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
CA3151394C (en) Pharmaceutical constructs with enhanced binding affinity with albumin
WO2024150175A1 (en) Conditionally activated proteins and methods of use
US20040110671A1 (en) N-terminal modified recombinant human endostatin and its production
CN117616036A (zh) 用于治疗炎性疾病和自身免疫性疾病的修饰的il-2多肽
US20250186594A1 (en) Il-18 polypeptides modified with polymers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260218